¼¼°èÀÇ ÀǾàǰ Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå
Pharmaceutical Manufacturing Software
»óǰÄÚµå : 1744822
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀǾàǰ Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2030³â±îÁö 45¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 30¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÀǾàǰ Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 45¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠŬ¶ó¿ìµå ¹èÆ÷´Â CAGR 5.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿ÂÇÁ·¹¹Ì½º ¹èÆ÷ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 9.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 1,960¸¸ ´Þ·¯, Áß±¹Àº CAGR 10.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ÀǾàǰ Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2024³â¿¡ 8¾ï 1,960¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 10.5%·Î, 2030³â±îÁö 9¾ï 2,230¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.5%¿Í 6.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀǾàǰ Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼ÒÇÁÆ®¿þ¾î°¡ ÃֽŠÀǾàǰ Á¦Á¶ »ýŰèÀÇ Áß½ÉÀÌ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Á¦¾à Á¦Á¶ ºÐ¾ß´Â µðÁöÅÐ Àüȯ±â¸¦ ¸ÂÀÌÇϰí ÀÖÀ¸¸ç, Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î´Â ÀÌ·¯ÇÑ º¯È­¸¦ ½ÇÇöÇÏ´Â ÇÙ½É ¿ä¼Ò·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦, ¸ÂÃãÇü ÀÇ·á, ¾ö°ÝÇÑ ±ÔÁ¦ ¸ð´ÏÅ͸µÀ¸·Î ÀÎÇØ Á¦Á¶ÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¦Á¶¾÷üµéÀº ¹èÄ¡ ÇÁ·Î¼¼½º ÃÖÀûÈ­, ÆíÂ÷ ÃßÀû, Àåºñ ¸ð´ÏÅ͸µ, ±ÔÁ¤ Áؼö º¸ÀåÀ» À§ÇÑ Àü¹® ¼ÒÇÁÆ®¿þ¾î Ç÷§Æû¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Á¦Á¶ ½ÇÇà ½Ã½ºÅÛ(MES), Àü»çÀû ÀÚ¿ø °ü¸®(ERP), ÇÁ·Î¼¼½º ºÐ¼® ±â¼ú(PAT) ¸ðµâ¿¡ °ÉÃÄ ½Ç½Ã°£ °¡½Ã¼º, µ¥ÀÌÅÍ ¹«°á¼º, ÀÚµ¿È­ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù.

·¹°Å½Ã Á¦Á¶ ¼³Á¤Àº Áß¾Ó ÁýÁᫎ Á¦¾î ¹× ¿¹Ãø ºÐ¼®À» °¡´ÉÇÏ°Ô Çϴ Ŭ¶ó¿ìµå ±â¹Ý IoT ÅëÇÕ Ç÷§ÆûÀ¸·Î ´ëü ¹× ¾÷±×·¹À̵åµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº Àåºñ ¹× ÀÎÀû ÀÚ¿øÀÇ ½ºÄÉÁÙ¸µÀ» °ü¸®ÇÒ »Ó¸¸ ¾Æ´Ï¶ó µðÁöÅÐ ¹èÄ¡ ±â·ÏÀ» Á¦°øÇϰí, ¹®¼­È­¸¦ ÀÚµ¿È­Çϸç, ½ÇÇè½Ç Á¤º¸ ½Ã½ºÅÛ(LIMS)°ú ÅëÇÕÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¬¼Ó »ý»ê°ú ¸ðµâ½Ä »ý»êÀÌ ´ëÁßÈ­µÊ¿¡ µû¶ó ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀº Á¾À̰¡ ÇÊ¿ä ¾ø°í, ±ÔÁ¤À» ÁؼöÇϸç, À¯¿¬ÇÑ Á¦Á¶ ȯ°æÀ» ±¸ÇöÇÏ´Â µ¥ ÀÖÀ¸¸ç, ±âº»ÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

±ÔÁ¦ ¾Ð·Â, µ¥ÀÌÅÍ ¹«°á¼º ¿ä±¸, Àδõ½ºÆ®¸® 4.0 Ç¥ÁØÀº ¾î¶»°Ô ¼ÒÇÁÆ®¿þ¾î äÅÃÀ» ÃËÁøÇϰí Àִ°¡?

FDA, EMA, MHRA¿Í °°Àº ÀǾàǰ ±ÔÁ¦ ´ç±¹Àº µ¥ÀÌÅÍ ÃßÀû¼º, °¨»ç ÃßÀû, ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» Á¡Á¡ ´õ Áß¿ä½ÃÇϰí ÀÖ½À´Ï´Ù. ÀǾàǰ Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î´Â ¾ÈÀüÇÑ Á¢±Ù Á¦¾î, ÀÚµ¿È­µÈ ±â·Ï °ü¸®, ÀüÀÚ ¼­¸íÀ» º¸ÀåÇÔÀ¸·Î½á ÀǾàǰ Á¦Á¶ ¹× ǰÁú°ü¸® ±âÁØ(GMP), 21 CFR Part 11, Annex 11À» ÁؼöÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ±ÔÁ¦±â°üÀÇ µ¥ÀÌÅÍ ¹«°á¼º °ü·Ã °æ°íÀåÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ÒÇÁÆ®¿þ¾î ÅëÇÕÀÇ ½Ã±Þ¼ºÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

AI, µðÁöÅÐ Æ®À©, ¸Ó½Å·¯´×°ú °°Àº Àδõ½ºÆ®¸® 4.0 ±â¼úÀº 󸮷®À» ÃÖÀûÈ­ÇÏ°í ´Ù¿îŸÀÓÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ Á¦¾à Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î¿¡ ÅëÇյǾî ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº Àåºñ °íÀåÀ» ¿¹ÃøÇϰí, °øÁ¤ ÆÄ¶ó¹ÌÅ͸¦ µ¿ÀûÀ¸·Î Á¶Á¤Çϰí, ÀÎÀû ¿À·ù¸¦ ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ¸ç, MES¿Í °í±Þ ºÐ¼®ÀÇ Á¶ÇÕÀº ¼¼Æ÷¹è¾ç ¹× Áß¿ä ǰÁú Ư¼º(CQA)ÀÇ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ Á¤È®ÇÏ°Ô °ü¸®ÇØ¾ß ÇÏ´Â »ý¹°Á¦Á¦¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ƯÈ÷ Áß¿äÇÕ´Ï´Ù. Á¦Á¶¾÷üµéÀÌ ½º¸¶Æ® ÆÑÅ丮¿Í ºÐ»êÇü »ý»ê ¸ðµ¨À» äÅÃÇÔ¿¡ µû¶ó ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î ¿¡ÄڽýºÅÛÀº ÀǾàǰ Á¦Á¶ ÀÎÅÚ¸®Àü½ºÀÇ ÁßÃß°¡ µÇ°í ÀÖ½À´Ï´Ù.

È®À强, »óÈ£¿î¿ë¼º, Ŭ¶ó¿ìµå Ç÷§ÆûÀÌ ¼ÒÇÁÆ®¿þ¾î Àü·«À» ÀçÁ¤ÀÇÇÏ´Â ÀÌÀ¯´Â?

¿©·¯ Áö¿ª°ú Á¦Ç° Ä«Å×°í¸®¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â Á¦¾à»ç¿¡°Ô È®À强°ú ½Ã½ºÅÛ »óÈ£¿î¿ë¼ºÀº ÃÖ¿ì¼± °úÁ¦ÀÔ´Ï´Ù. ÃֽмÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀº ±âÁ¸ ERP, SCADA, SCADA, DCS, LIMS Ç÷§Æû°ú ¿øÈ°ÇÏ°Ô ÅëÇÕÇÒ ¼ö ÀÖ´Â ¸ðµâ½Ä ¾ÆÅ°ÅØÃ³·Î ¼³°èµÇ¾î ÆÄÀÏ·µ ±Ô¸ð¿¡¼­ »ó¾÷Àû ±Ô¸ð±îÁö È®ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. °³¹æÇü API¿Í ¸ÂÃãÇü ÀÎÅÍÆäÀ̽º ¿É¼ÇÀº Á¦¾àȸ»ç°¡ Á¦Á¶, ǰÁú, °ø±Þ¸Á, R&D¿¡ °ÉÄ£ Çù¾÷ µ¥ÀÌÅÍ »ýŰ踦 À°¼ºÇÏ´Â µ¿½Ã¿¡ º¥´õ Á¾¼ÓÀ» ÇÇÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

Ŭ¶ó¿ìµå ±â¹Ý µµÀÔÀº ºñ¿ë Àý°¨, ºü¸¥ ±¸Çö, »çÀ̹ö º¸¾È °­È­¸¦ ÅëÇØ ¼ÒÇÁÆ®¿þ¾î Á¦°ø ¸ðµ¨À» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº Áß¾Ó ÁýÁᫎ µ¥ÀÌÅÍ ÀúÀå, ½Ç½Ã°£ Çù¾÷, ¿ø°Ý °ËÁõ ±â´ÉÀ» Á¦°øÇϸç, ƯÈ÷ ºÐ»êµÇ°í ¹ÎøÇÑ ¿î¿µÀ» ¼±È£ÇÏ´Â ÆÒµ¥¹Í ÀÌÈÄ »óȲ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. º¥´õµéÀº SaaS ±â¹Ý ÄÄÇöóÀ̾𽺠¸ðµâ, ¸ð¹ÙÀÏ Á¢±ÙÀÌ °¡´ÉÇÑ ´ë½Ãº¸µå, ±¸¼º °¡´ÉÇÑ ÅÛÇø´À» Á¦°øÇÏ¿© Áß°ß Á¦Á¶¾÷ü ¹× CDMO(À§Å¹ °³¹ß ¹× Á¦Á¶ ±â°ü)¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

Á¦¾à Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼¼°è ¼ºÀå µ¿·ÂÀº?

Á¦¾à Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀåÀº ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­, ½Ç½Ã°£ °øÁ¤ ÃÖÀûÈ­¿¡ ´ëÇÑ ¼ö¿ä, Á¦Á¶ ȯ°æÀÇ µðÁöÅÐÈ­·ÎÀÇ ±¤¹üÀ§ÇÑ Àüȯ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ÄÄÇöóÀ̾ð½º, È¿À²¼º, µ¥ÀÌÅͺ£À̽º ÀÇ»ç°áÁ¤ÀÇ À¶ÇÕÀ¸·Î, Á¦Á¶ ¿öÅ©Ç÷οì¿Í ¿øÈ°ÇÏ°Ô ÅëÇյǴ °­·ÂÇÑ µðÁöÅÐ Ç÷§ÆûÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

Á¦¾à»çµéÀÌ ¹ÙÀÌ¿ÀÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀ» È®ÀåÇϰí, Áö¼ÓÀûÀÎ Á¦Á¶¿¡ ÅõÀÚÇϰí, Á¦Á¶¸¦ Á¦3ÀÚ °ø±Þ¾÷ü¿¡ À§Å¹ÇÔ¿¡ µû¶ó º¹À⼺, À§Çè, µ¥ÀÌÅÍ Ãæ½Çµµ¸¦ °ü¸®ÇÒ ¼ö ÀÖ´Â ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î ½Ã½ºÅÛÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀüÀº ÀÌ·¯ÇÑ Ç÷§ÆûÀÇ ´É·ÂÀ» ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. µðÁöÅÐ ÀÎÇÁ¶ó, Ŭ¶ó¿ìµå Çõ½Å, Pharma 4.0 ±¸»ó¿¡ ´ëÇÑ ÅõÀÚ°¡ È®´ëµÊ¿¡ µû¶ó Á¦¾à Á¦Á¶ ¼ÒÇÁÆ®¿þ¾î´Â ¼¼°è »ý¸í°úÇÐ »ý»ê ¹ë·ùüÀο¡¼­ ÇʼöÀûÀÎ ÀÚ»êÀÌ µÉ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

¹èÆ÷(Ŭ¶ó¿ìµå, ¿ÂÇÁ·¹¹Ì½º), Á¶Á÷ ±Ô¸ð(´ë±â¾÷, Áß¼Ò±â¾÷), ÃÖÁ¾»ç¿ëÀÚ(¹ÙÀÌ¿ÀÀǾàǰ ȸ»ç, ÀÇ·á±â±â ȸ»ç, °è¾à ¿¬±¸±â°ü, Çмú¿¬±¸±â°ü, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 44°Ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <gt; Áß±¹ <gt; ¸ß½ÃÄÚ <gt; ij³ª´Ù <gt;EU <gt; ÀϺ» <gt; Àεµ <gt; ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pharmaceutical Manufacturing Software Market to Reach US$4.5 Billion by 2030

The global market for Pharmaceutical Manufacturing Software estimated at US$3.0 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Cloud Deployment, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the On-Premise Deployment segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$819.6 Million While China is Forecast to Grow at 10.5% CAGR

The Pharmaceutical Manufacturing Software market in the U.S. is estimated at US$819.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$922.3 Million by the year 2030 trailing a CAGR of 10.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Pharmaceutical Manufacturing Software Market - Key Trends & Drivers Summarized

Why Is Software Becoming Central to Modern Pharmaceutical Manufacturing Ecosystems?

The pharmaceutical manufacturing sector is undergoing a digital transformation, and manufacturing software is emerging as a vital enabler of this shift. As production complexity rises with biologics, personalized medicine, and stringent regulatory scrutiny, manufacturers are increasingly turning to specialized software platforms to optimize batch processes, track deviations, monitor equipment, and ensure compliance. These systems offer real-time visibility, data integrity, and automation capabilities across manufacturing execution systems (MES), enterprise resource planning (ERP), and process analytical technology (PAT) modules.

Legacy manufacturing setups are being replaced or upgraded with cloud-based, IoT-integrated platforms that enable centralized control and predictive analytics. These tools not only manage equipment and human resource scheduling but also provide digital batch records, automate documentation, and integrate with laboratory information systems (LIMS). As continuous manufacturing and modular production gain traction, software platforms are playing a foundational role in enabling paperless, compliant, and flexible manufacturing environments.

How Are Regulatory Pressures, Data Integrity Demands, and Industry 4.0 Standards Driving Software Adoption?

Pharmaceutical regulators such as the FDA, EMA, and MHRA are placing growing emphasis on data traceability, audit trails, and real-time monitoring-mandates that are difficult to fulfill without robust digital infrastructure. Pharmaceutical manufacturing software enables compliance with Good Manufacturing Practices (GMP), 21 CFR Part 11, and Annex 11 by ensuring secure access control, automated recordkeeping, and electronic signatures. The rising number of data integrity warning letters from regulatory bodies underscores the urgency of software integration.

Industry 4.0 technologies-such as AI, digital twins, and machine learning-are being embedded into pharmaceutical manufacturing software to optimize throughput and minimize downtime. These tools help predict equipment failures, adjust process parameters dynamically, and reduce human error. The combination of MES and advanced analytics is especially critical in biologics, where real-time data from cell cultures and critical quality attributes (CQAs) must be managed with precision. As manufacturers adopt smart factories and decentralized production models, integrated software ecosystems are becoming the backbone of pharmaceutical manufacturing intelligence.

Why Are Scalability, Interoperability, and Cloud Platforms Redefining Software Strategies?

Scalability and system interoperability are top priorities for pharmaceutical firms operating across multiple geographies and product categories. Modern software solutions are designed with modular architectures that allow scalability from pilot to commercial scale, while enabling seamless integration with existing ERP, SCADA, DCS, and LIMS platforms. Open APIs and custom interface options are helping pharmaceutical companies avoid vendor lock-in while fostering collaborative data ecosystems across manufacturing, quality, supply chain, and R&D.

Cloud-based deployments are transforming software delivery models, offering cost savings, faster implementation, and enhanced cybersecurity. These platforms allow centralized data storage, real-time collaboration, and remote validation capabilities, especially important in a post-pandemic landscape that favors decentralized, agile operations. Vendors are increasingly offering SaaS-based compliance modules, mobile-access dashboards, and configurable templates to cater to mid-size manufacturers and contract development and manufacturing organizations (CDMOs).

What’s Driving the Global Growth of the Pharmaceutical Manufacturing Software Market?

The growth in the pharmaceutical manufacturing software market is driven by several factors including increased regulatory scrutiny, demand for real-time process optimization, and the broader shift toward digitalized manufacturing environments. A major growth driver is the convergence of compliance, efficiency, and data-driven decision-making-necessitating robust digital platforms that integrate seamlessly with manufacturing workflows.

As pharmaceutical companies expand biologics pipelines, invest in continuous manufacturing, and outsource production to third-party providers, the need for integrated software systems to manage complexity, risk, and data fidelity becomes critical. Technological advancements in AI, blockchain, and edge computing are further amplifying the capabilities of these platforms. With growing investments in digital infrastructure, cloud transformation, and Pharma 4.0 initiatives, pharmaceutical manufacturing software is poised to become an indispensable asset in the global life sciences production value chain.

SCOPE OF STUDY:

The report analyzes the Pharmaceutical Manufacturing Software market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Deployment (Cloud, On-Premise); Organization Size (Large Enterprises, SMEs); End-Use (Biopharmaceutical Companies, Medical Device Companies, Contract Research Organizations, Academic Research Institutions, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â